Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Zymosan A, derived from Saccharomyces cerevisiae, is a TLR2 agonist and exhibits significant radioprotective effects, mitigating and preventing IR-induced intestinal injury in mice. Furthermore, Zymosan A aids in the regeneration of intestinal stem cells (ISCs) following IR injury [1].
Description | Zymosan A, derived from Saccharomyces cerevisiae, is a TLR2 agonist and exhibits significant radioprotective effects, mitigating and preventing IR-induced intestinal injury in mice. Furthermore, Zymosan A aids in the regeneration of intestinal stem cells (ISCs) following IR injury [1]. |
In vivo | Zymosan A is utilized in animal modeling to establish a mouse model of peritonitis. Administered at a dose of 25.0 mg/kg through intraperitoneal injection 12 hours and 2 hours before ischemia-reperfusion (IR) stress, Zymosan A mitigates IR-induced intestinal damage in mice [1]. |
Synonyms | Zymosan A from Saccharomyces cerevisiae |
Molecular Weight | N/A |
CAS No. | 58856-93-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Zymosan A 58856-93-2 Zymosan A from Saccharomyces cerevisiae inhibitor inhibit